Genentech adds to autoimmune pipeline with Parvus deal

In its second deal based on its immunomodulatory platform, Parvus granted Genentech rights to develop and commercialize its Navacim nanoparticle therapeutics to treat inflammatory bowel disease (IBD), autoimmune liver

Read the full 294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE